'Living' History: Breakthrough CAR-T Application Breaks Through In National Media
Executive Summary
FDA advisory committee meetings aren’t often front page news. But the Oncologic Drugs Advisory Committee review of the first CAR-T therapy was on the front page of both the Washington Post and the New York Times. Both headlines describe it as a “living drug.”
You may also be interested in...
Cornering The Market On Innovation? The First CAR-T And The First Gene Therapy
It isn’t just the cutting-edge science. Novartis’ landmark approval also highlights regulatory and reimbursement innovation and also may set the rules that the next wave of cell and gene therapies have to follow.
Kite’s Axi-Cel CAR-T: No Adcomm, No Problem
Next CAR-T in line at US FDA, Kite’s axicabtagene ciloleucel, looks headed toward an early approval with the agency confirming no panel will be scheduled, according to the firm. But the company and FDA may have benefited from an advisory committee review.
More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals
Sponsors of established products like Amgen's Kyprolis and Blincyto and Bristol's Sprycel work to bulk up labeling with new indications while FDA reviews at least six novel agents for blood cancers.